ScoreWhy is Corona Remedies Ltd ?
1
Flat results in Mar 26
- PBT LESS OI(Q) At Rs 50.63 cr has Fallen at -15.8% (vs previous 4Q average)
2
With ROE of 26.8, it has a Very Expensive valuation with a 13.9 Price to Book Value
3
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 0.66% over the previous quarter and collectively hold 9.26% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Corona Remedies should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
27.90
Debt to EBITDA (avg)
0.56
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.54
Tax Ratio
23.03%
Dividend Payout Ratio
30.00%
Pledged Shares
0
Institutional Holding
16.53%
ROCE (avg)
29.49%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
60
Industry P/E
37
Price to Book Value
17.05
EV to EBIT
50.25
EV to EBITDA
43.76
EV to Capital Employed
14.82
EV to Sales
9.15
PEG Ratio
NA
Dividend Yield
0.48%
ROCE (Latest)
29.49%
ROE (Latest)
26.75%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Mildly Bullish
KST
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
NET SALES(Q)
Highest at Rs 422.43 cr
PBDIT(Q)
Highest at Rs 93.13 cr.
PBT LESS OI(Q)
Highest at Rs 77.21 cr.
PAT(Q)
Highest at Rs 60.11 cr.
EPS(Q)
Highest at Rs 9.83
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Corona Remedies
Net Sales - Quarterly
Highest at Rs 422.43 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 422.43 cr has Grown at 20.4% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 350.80 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 93.13 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 77.21 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 77.21 cr has Grown at 24.1% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 62.22 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 60.11 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 60.11 cr has Grown at 20.6% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 49.85 CrMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 9.83
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
